Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572975 · ClinicalTrials.gov registry record · Phase 4
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
A Phase 4 study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00572975: Completed Phase 4 study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by Children's Hospital of Philadelphia.
NCT00572975 is a Phase 4 study of Cystic Fibrosis and Pancreatic Insufficiency that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 9 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572975, a Phase 4 study of Cystic Fibrosis and Pancreatic Insufficiency, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
\*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.
Conditions Studied
Interventions
- OTHER Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00572975 record still lists
NCT00572975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Pentadecanoic acid (PA) and Triheptadecanoin (THA) is the first listed.
NCT00572975 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00572975 about?
NCT00572975 is a clinical study titled "Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea". \*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.
What is the current status of trial NCT00572975?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2006-08. Estimated completion is 2008-03.
What conditions does trial NCT00572975 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Pancreatic Insufficiency.
What interventions are being tested in trial NCT00572975?
The interventions under investigation include: Pentadecanoic acid (PA) and Triheptadecanoin (THA) (OTHER).
Who is sponsoring clinical trial NCT00572975?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572975 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00572975's enrollment target sits among peer trials
9 162nd of 169 higher than 6 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia